Chief Executive Officer
Jan Dekker studied Law (Candidate of Law) at Utrecht University after which he became an MBA at IIB Delft. He held several management positions at, among others, Medicopharma, Hoek Loos (Linde Gas), Allegiance and Cardinal health. He was CEO at Mediq pharma before joining Cergentis at the end of 2018 as CEO.
Max van Min received a Master of Science degree in Biotechnology from Wageningen University & Research Centre and has previously worked in management positions at Keygene and the life sciences multinational DSM. He is co-inventor of the TLA technology.
He oversees Cergentis' intellectual property, product development, business development & marketing.
Chief Technology Officer
Erik Splinter has, both at the Erasmus MC and the Hubrecht Institute, worked extensively on the development and optimisation of technologies for the analysis of 3D structures of human genomes. He has co-authored peer-reviewed publications in, among others, Genes & Development, Molecular Cell, and Nature Genetics.
At Cergentis, in his role as CTO, Erik is primarily responsible for the further development of the TLA technology and its various applications.
Chief Financial Officer
Jean-Marc Roelandt received a Master’s degree in Applied Economics from the Ghent University and started his career as a Certified Public Accountant at EY. Before joining Cergentis as CFO at the end of 2019, he held several senior management positions in publicly listed companies, including BHF Kleinwort Benson and MDxHealth.
Head of Bioinformatics
Marieke Simonis performed her doctoral training at the Erasmus MC, where she developed protocols and analyses methods for 3C based technologies. She performed her post-doctoral work at the Hubrecht Institute, specializing in bioinformatics and the analysis and interpretation of Next Generation Sequencing data. She has co-authored in, among others, Nature Genetics and Nature Methods.
Head of Business Development Oncology
Harma received an MSc degree in Biotechnology from Wageningen University and a PhD on genomics/oncogenetics in zebrafish from the Hubrecht Institute. Previously, she worked for almost 10 years at Philips; as senior scientist in molecular and precision diagnostics, in the development of diagnostic products in oncology and next generation sequencing. She co-authored several publications and patent applications.
At Cergentis, in her role as Head of Business Development Oncology, Harma is primarily responsible for the definition and development of new products using TLA in oncology research and diagnostics.
Head of Services
Judith Bergboer received her PhD in human genetics and molecular biology from the Radboud University Nijmegen. She performed her post-doctoral studies at Harvard Medical School, where she generated and studied several transgenic and mutant zebrafish lines. She has co-authored in, among others, PLoS Genetics and Nature Genetics.
International Sales Manager
Martijn Kelder obtained his MSc in molecular genetics from Utrecht University, after which he further specialised in the mechanisms of genome editing using CRISPR/Cas9 during his doctoral training at the University of Edinburgh. He has co-authored in several journals including PLoS Biology and Nature Protocols.
As International Sales Manager at Cergentis, Martijn is responsible for both the development of sales and managing the existing portfolio of accounts.
Petra has many years of practical experience working as a research technician at the Erasmus MC and as a lab manager at the Hubrecht Institute. She has worked on different research projects on the 3D organisation of the genome and contributed to the development and optimisation of new techniques. She joined Cergentis after receiving a Masters degree in Cancer Genomics and Developmental Biology from Utrecht University.
Mehmet Yilmaz received a Bachelors degree in Life Sciences with a minor in Microbiology from the University of Applied Sciences in Utrecht, The Netherlands. He was one of the first technicians to join Cergentis and has worked extensively on the optimisation of the TLA protocol on both cells and isolated genomic DNA.
At Cergentis, Mehmet is working as a product developer on the optimisation of the TLA technology for various applications.
Scientific Account Manager
Irina Sergeeva received her Ph.D. in molecular biology at the University of Amsterdam, where she studied the mechanisms of cardiac hypertrophy and repair. She generated several transgenic mouse reporter lines for in vitro and in vivo analysis, and used 4C-seq technology to study gene regulation in the heart.
Elaine Wong studied Biomedical Sciences at Utrecht University. She received a PhD in molecular biology at the University of Amsterdam, where she studied the transcriptional pathways in the development of the heart. She developed and optimized technologies for the identification of whole-genome protein-DNA binding profiles.
At Cergentis, Elaine works as part of the service projects team performing TLA and data analysis for our customers.
Research Technician / Product Developer
Melinda Aprelia received her Bachelor degree in Life Sciences from HAN University of Applied Sciences in Nijmegen. She worked previously as a research technician at the UMC Utrecht and the Netherlands Cancer Institute, where she worked on several projects to understand the molecular mechanism of cell division in response to DNA damage.
After receiving her Masters degree in cancer genomics and developmental biology from the Utrecht University, Vera attended a PhD program at the NKI. During her PhD she focused on the role of DNA repair mechanisms in telomere dysfuncion. She identified a new factor involved in DNA repair of double strand breaks which led to a publication in Nature.
At Cergentis Vera is working as a product developer on the optimisation of the TLA technology for oncogenetic applications.
Product Developer Oncology
Joost Swennenhuis received his PhD from the University of Twente with research in the field oncology and liquid biopsy, focusing on the isolation and molecular analysis of circulating tumor cells. Formerly Joost has developed products for Immunicon corp in Enschede and Kreatech biotechnology (Now Leica) in Amsterdam and has worked at Veterinary Pathology of the University of Utrecht.
At Cergentis, Joost is working as a product developer on the optimisation of the TLA technology for oncology applications.
Cheryl Dambrot received her PhD from Leiden University with research in the field of stem cell biology, focusing on generating induced pluripotent stem cells to model cardiac disease. She performed her post-doctoral study at the Yale Stem Cell Center, where she investigated the mechanism behind mouse and human cellular reprogramming.
At Cergentis, Cheryl works as part of the service projects team performing TLA and data analysis for our customers.
Marketing Operations Manager
Wietske Stevens received her Bachelor Degree in International Communication Management from The Hague University of Applied Sciences and a Master of Science degree in Communication Sciences from VU Amsterdam. She worked as content creator and editor for online magazines, and has experience in both online and offline marketing communication activities as well as writing and executing strategic communication plans.
At Cergentis, she is responsible for marketing & communication related operations.